AI Summary
This article discusses the design, synthesis, and biological evaluation of potent EZH2/LSD1 dual inhibitors for prostate cancer. The study focuses on developing compounds that can effectively target both EZH2 and LSD1 enzymes, which play key roles in cancer progression. The goal is to create a new class of inhibitors that can potentially improve treatment outcomes for prostate cancer patients.